Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trial
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15768 ↗At a glance
Randomisierte kontrollierte Studie in Diabetes, Obesity and Metabolism, 2024. Written by Amir Razaghizad and 12 co-authors. Institution: Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada. Major MEDLINE topics: Diabetes Mellitus, Type 2, Canagliflozin, Phenotype, Sodium-Glucose Transporter 2 Inhibitors. Cited 6 times so far (Crossref); 26 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Dr. Clarke K. McLeod Memorial Scholarship Fund, Mach-Gaensslen Foundation of Canada Scholarship, Canada Research Chairs Program.
Topics: Diabetes mellitus
Abstract (original language)
Aim
To identify unique clinical phenotypes in type 2 diabetes (T2D) and investigate their treatment response to canagliflozin using latent class analysis.
Methods
This was a pooled latent class analysis of the individuals in the CANVAS Program and CREDENCE trial. The co‐primary endpoints were hospitalization for heart failure (HHF) and the composite of cardiovascular death (CVD) or HHF. Secondary endpoints included three‐point major adverse CV events, its individual components, and all‐cause mortality. We completed Cox proportional hazards models to evaluate the effect of canagliflozin across phenotypes.
Results
Four distinct phenotypes were identified: Phenotype 1 ( n = 966, 6.6%), with the lowest prevalence of heart failure, kidney dysfunction and hypertension; Phenotype 2 ( n = 4169, 28.7%), primarily comprising females with a high prevalence of atherosclerotic vascular disease (ASCVD); Phenotype 3 ( n = 7108, 48.9%), predominately males with a high prevalence of ASCVD; and Phenotype 4 ( n = 2300, 15.8%), possessing the highest prevalences of HF and renal dysfunction. A hierarchical increase in the risk of the primary endpoint was observed across the phenotypes, with the highest CV risk observed for Phenotype 4 (hazard ratio for HHF: 7.57 [95% CI: 4.19‐13.69]). Canagliflozin significantly reduced HHF and the composite CVD or HHF across phenotypes (all P values for interaction > .05).
Conclusion
We identified four clinically distinct T2D phenotypes with differential CV risks. Canagliflozin reduced the risk of CV events, irrespective of the phenotype, emphasizing its broad therapeutic acceptability.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
- Department of Medicine, McGill University, Montreal, Quebec, Canada.
- Division of Cardiology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada.
- Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal.
- Department of Internal Medicine, Centro Hospitalar Universitário de S. João, Porto, Portugal.
- Division of Nephrology, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada.
ORCID profiles: Amir Razaghizad, Pedro Marques, Michael A Tsoukas, Frederic Baroz, João Pedro Ferreira, Abhinav Sharma
Funding
- Dr. Clarke K. McLeod Memorial Scholarship Fund
- Mach-Gaensslen Foundation of Canada Scholarship
- Canada Research Chairs Program
- Ontario Ministry of Colleges and Universities
- Canada Brain Research Fund
Cite
APA
Razaghizad, A., Ni, J., Marques, P., Mavrakanas, T. A., Tsoukas, M. A., Possik, E., Huynh, T., Edwards, J. D., Liu, P., Swardfager, W., Baroz, F., Ferreira, J. P., & Sharma, A. (2024). Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15768
Vancouver
Razaghizad A, Ni J, Marques P, Mavrakanas TA, Tsoukas MA, Possik E, et al. Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trial. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15768
BibTeX
@article{Razaghizad2024,
author = {Razaghizad, Amir and Ni, Jiayi and Marques, Pedro and Mavrakanas, Thomas A and Tsoukas, Michael A and Possik, Elite and Huynh, Thao and Edwards, Jodi D and Liu, Peter and Swardfager, Walter and Baroz, Frederic and Ferreira, João Pedro and Sharma, Abhinav},
title = {Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trial},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15768}
}
EUVIMED